Multiplexed, Rapid, Point of Care Device to Quantify Specific IgE to Common Aller

描述（由申请人提供）：提议研究的主要目标是开发一种校准，紧凑，廉价，多路复用，护理点传感平台，结合荧光和无标签功能，适用于医学诊断领域。使用具有体外和临床证据的个体血清作为模型系统，我们将开发一个点护理平台，将我们建立的无标签传感技术与我们的增强荧光技术，校准荧光增强（CaFE）相结合。我们建议，该平台将更准确和灵敏地检测特异性抗体的存在感兴趣的蛋白质。点护理能力将允许有效的技术应用和提高病人的护理。当前测试的局限性在于在远离护理点的临床或参考实验室中使用荧光测量，而捕获感兴趣的蛋白质（例如抗体）的探针尚未经过校准，并且芯片之间各不相同。此外，目前可用的定量无标签传感器仅限于灵敏度水平超过设备的噪声底限。这项工作将设计一种校准仪器，它结合了双重模式，以改进现有的诊断技术。虽然以过敏诊断为模型，但其基础技术是模块化的，可以应用于肝脏疾病和自身免疫性疾病的免疫诊断。

DESCRIPTION (provided by applicant): The major goal of the proposed research is to develop a calibrated, compact, inexpensive, multiplexed, point- of-care sensing platform with combined fluorescence and label-free capabilities applicable to the field of medical diagnostics. Using sera from individuals with documented in vitro and clinical evidence of allergen- specific IgE as a model system, we will develop a point-of-care platform that combines our established label- free sensing technology with our enhanced fluorescence technology, Calibrated Fluorescence Enhancement (CaFE). We propose that this platform will more accurately and sensitively detect the presence of specific antibodies to proteins of interest. The point-of-care capability will allow efficient technology application and enhance patient care. Limitations of current tests reside in utilizing fluorescence measurements in a clinical or reference laboratory away from the point-of-care, while the probes capturing the proteins (e.g. antibodies) of interest have not been calibrated and vary from chip to chip. In addition, currently available quantitative label-free sensors are limited to sensitivity levels surpassing the noise floor of the device. This work will engineer a calibrated instrument, which incorporates dual modalities to improve upon existing diagnostic technology. While using allergy diagnostics as a model, the underlying technology is modular, and could be applied to immunodiagnostics of liver disease and autoimmune disease. PUBLIC HEALTH RELEVANCE (provided by applicant): The goal of the proposed research is to develop a modular platform to more accurately diagnose medical conditions at the point of care. Many assays which detect pathologic antibodies in the blood rely on unknown quantities of 'capture' proteins to measure these antibodies. The proposed technology will quantify results calibrated against the directly measured amount of capture protein, all at the point-of-care and in the context of a physician visit.